Search

Displaying results 2771 - 2780 of 10000 in total
  1. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  2. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  3. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    [A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and

  4. Drug

    Rimantadine

    go.drugbank.com/drugs/DB00478
    Approved

    An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.

  5. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval. … [A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form.

  6. Target

    Platelet-activating factor acetylhydrolase

    go.drugbank.com/bio_entities/BE0002409
    TargetHumans

    Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a potent pro-inflammatory signaling lipid that acts through PTAFR on various innate immune cells

    Synonyms: PAF 2-acylhydrolase, PAF acetylhydrolase
  7. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    This drug was approved in July 2010.

  8. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    FDA approved on March 6, 2012.

  9. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting … THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased

  10. Drug

    Solriamfetol

    go.drugbank.com/drugs/DB14754
    ApprovedInvestigational

    Solriamfetol was given FDA approval in 2019[FDA Label]. … Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated